Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 98 of 114

  1. UC-0103/1802

    Ningbo Cancer Hospital

    Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years old

    phase 3 small molecule active

    1 trial

  2. UC-0107/1718

    Ningbo Cancer Hospital

    Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 antagonist (pembrolizumab) according to the European Marketing Authorisation in a first line

    phase 3 small molecule active

    1 trial

  3. UC-0110/1609

    Ningbo Cancer Hospital

    High-risk stage III colon cancer

    phase 3 small molecule active

    1 trial

  4. UC-0140/1615

    Ningbo Cancer Hospital

    ER+/HER2- metastatic breast cancer

    phase 3 small molecule active

    1 trial

  5. UC-0140/1901

    Ningbo Cancer Hospital

    Patients with untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement

    phase 3 small molecule active

    1 trial

  6. UC-0160/1003

    Ningbo Cancer Hospital

    Prostatic adenocarnicoma with high risk of recurrence

    phase 3 small molecule active

    1 trial

  7. UC-BCG-2409/BIG 2402

    Ningbo Cancer Hospital

    Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.

    phase 3 small molecule active

    1 trial

  8. UC-BCG-2501

    Ningbo Cancer Hospital

    Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  9. UC-GIG-2406

    Ningbo Cancer Hospital

    Patients with hepatocellular carcinoma with high tumor burden.

    phase 3 small molecule active

    1 trial

  10. UC-GIG-2408

    Ningbo Cancer Hospital

    Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy, FOLFOX chemotherapy and total mesorectal excision (TME) surgery

    phase 3 small molecule active

    1 trial

  11. UC-GIG-2410

    Ningbo Cancer Hospital

    Stage III colorectal cancer

    phase 3 small molecule active

    1 trial

  12. UC-GTG-2301

    Ningbo Cancer Hospital

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  13. UC-GTG-2306

    Ningbo Cancer Hospital

    Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

    phase 3 small molecule active

    1 trial

  14. UC-IMM-2101

    Ningbo Cancer Hospital

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  15. UDCA

    The First People's Hospital of Lianyungang

    Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  16. UGN-102 (Mitomycin)

    Lacuna Pharma Pty Ltd

    Non-Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  17. UGN-103 (Mitomycin)

    Lacuna Pharma Pty Ltd

    Nonmuscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  18. UGN-104

    Lacuna Pharma Pty Ltd

    Low-grade Upper Tract Urothelial Cancer

    phase 3 small molecule active

    1 trial

  19. UI022 or UI023 and co-administration of matching placebo

    United Therapeutics Europe Ltd

    Peripheral Arterial Disease

    phase 3 small molecule completed

    1 trial

  20. UI05MSP015CT

    United Therapeutics Europe Ltd

    Functional Dyspepsia

    phase 3 small molecule completed

    1 trial

  21. UIC-BKL-2013

    Universal Integrated

    Bowel Preparation Before Colonoscopy

    phase 3 small molecule completed

    1 trial

  22. UIC-STP-2017

    Universal Integrated

    Bowel Preparation

    phase 3 small molecule completed

    1 trial

  23. URO-901-3007

    Lacuna Pharma Pty Ltd

    Neurogenic Detrusor Overactivity (NDO)

    phase 3 small molecule active

    1 trial

  24. URONCOR 06-24

    The George Institute

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  25. UT-15

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule completed

    1 trial

  26. UT-15C (treprostinil diolamine)

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 3 small molecule completed

    1 trial

  27. UT-15C SR

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule completed

    1 trial

  28. UT-15C SR

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 3 small molecule completed

    3 trials

  29. UVEDOSE 100 000 UI, solution buvable en ampoule

    Novo Nordisk A/S

    Thyroidectomy is a common operation. Transient postoperative hypocalcemia is the main complication, resulting in clinical discomfort for patients, longer hospital stays and increased perioperative cost. Cholecalciferol is used to supplement vitamin D deficiency. We suppose that systematic pre-operative supplementation with cholecalciferol would allow a faster and more appropriate response to post-operative hypocalcemia

    phase 3 small molecule active

    1 trial

  30. UX003

    Ultragenyx UK Limited

    MPS 7

    phase 3 small molecule completed

    1 trial

  31. UX003

    Ultragenyx UK Limited

    Sly Syndrome

    phase 3 small molecule completed

    2 trials

  32. UX007

    Ultragenyx UK Limited

    Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

    phase 3 small molecule terminated

    2 trials

  33. UX111

    ABEONA THERAPEUTICS INC.

    MPS IIIA

    phase 3 mab active

    1 trial

  34. UX143-CL301

    Lacuna Pharma Pty Ltd

    Osteogenesis imperfecta (OI)

    phase 3 small molecule active

    1 trial

  35. Ublituximab

    TG THERAPEUTICS, INC.

    Diffuse Large B-Cell Lymphoma

    phase 3 mab terminated

    1 trial

  36. Ublituximab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    5 trials

  37. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis (RMS)

    phase 3 mab active

    3 trials

  38. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis

    phase 3 small molecule active

    3 trials

  39. Ublituximab, ublituximab

    TG THERAPEUTICS, INC.

    Relapsing forms of Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  40. Ultomiris 300 mg/3 mL concentrate for solution for infusion

    Alexion Europe SAS

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

    phase 3 small molecule active

    1 trial

  41. Ultomiris 300 mg/30 mL concentrate for solution for infusion

    Alexion Europe SAS

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy(HSCT- TMA)

    phase 3 small molecule active

    1 trial

  42. Unesbulin

    PTC Therapeutics International Limited

    Leiomyosarcoma

    phase 3 small molecule terminated

    1 trial

  43. Unesbulin

    PTC THERAPEUTICS, INC.

    Leiomyosarcoma

    phase 3 small molecule terminated

    2 trials

  44. Unified protocol for adolescents (UP-A)

    Chinese University of Hong Kong

    Depressive Disorder

    phase 3 other completed

    1 trial

  45. Upadacitinib

    AbbVie

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  46. Upadacitinib

    AbbVie

    Atopic Dermatitis

    phase 3 small molecule active

    3 trials

  47. Upadacitinib

    AbbVie

    Spondyloarthritis

    phase 3 small molecule completed

    1 trial

  48. Upadacitinib

    AbbVie

    Crohn's Disease

    phase 3 small molecule active

    2 trials

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.